LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 40

Search options

  1. Article: Genetics of Alzheimer's disease.

    Chouraki, Vincent / Seshadri, Sudha

    Advances in genetics

    2014  Volume 87, Page(s) 245–294

    Abstract: Alzheimer's disease (AD) represents the main form of dementia, and is a major public health problem. Despite intensive research efforts, current treatments have only marginal symptomatic benefits and there are no effective disease-modifying or preventive ...

    Abstract Alzheimer's disease (AD) represents the main form of dementia, and is a major public health problem. Despite intensive research efforts, current treatments have only marginal symptomatic benefits and there are no effective disease-modifying or preventive interventions. AD has a strong genetic component, so much research in AD has focused on identifying genetic causes and risk factors. This chapter will cover genetic discoveries in AD and their consequences in terms of improved knowledge regarding the disease and the identification of biomarkers and drug targets. First, we will discuss the study of the rare early-onset, autosomal dominant forms of AD that led to the discovery of mutations in three major genes, APP, PSEN1, and PSEN2. These discoveries have shaped our current understanding of the pathophysiology and natural history of AD as well as the development of therapeutic targets and the design of clinical trials. Then, we will explore linkage analysis and candidate gene approaches, which identified variants in Apolipoprotein E (APOE) as the major genetic risk factor for late-onset, "sporadic" forms of AD (LOAD), but failed to robustly identify other genetic risk factors, with the exception of variants in SORL1. The main focus of this chapter will be on recent genome-wide association studies that have successfully identified common genetic variations at over 20 loci associated with LOAD outside of the APOE locus. These loci are in or near-novel AD genes including BIN1, CR1, CLU, phosphatidylinositol-binding clathrin assembly protein (PICALM), CD33, EPHA1, MS4A4/MS4A6, ABCA7, CD2AP, SORL1, HLA-DRB5/DRB1, PTK2B, SLC24A4-RIN3, INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT2, CASS4, and TRIP4 and each has small effects on risk of AD (relative risks of 1.1-1.3). Finally, we will touch upon the ongoing effort to identify less frequent and rare variants through whole exome and whole genome sequencing. This effort has identified two novel genes, TREM2 and PLD3, and shown a role for APP in LOAD. The identification of these recently identified genes has implicated previously unsuspected biological pathways in the pathophysiology of AD.
    MeSH term(s) Alzheimer Disease/genetics ; Genetic Association Studies/methods ; Genetic Linkage ; Genetic Predisposition to Disease ; Genome-Wide Association Study/methods ; Humans ; Mutation ; Polymorphism, Single Nucleotide
    Language English
    Publishing date 2014-10-14
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 148-x
    ISSN 0065-2660
    ISSN 0065-2660
    DOI 10.1016/B978-0-12-800149-3.00005-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Incidence of Dementia over Three Decades in the Framingham Heart Study.

    Satizabal, Claudia L / Beiser, Alexa S / Chouraki, Vincent / Chêne, Geneviève / Dufouil, Carole / Seshadri, Sudha

    The New England journal of medicine

    2016  Volume 374, Issue 6, Page(s) 523–532

    Abstract: Background: The prevalence of dementia is expected to soar as the average life expectancy increases, but recent estimates suggest that the age-specific incidence of dementia is declining in high-income countries. Temporal trends are best derived through ...

    Abstract Background: The prevalence of dementia is expected to soar as the average life expectancy increases, but recent estimates suggest that the age-specific incidence of dementia is declining in high-income countries. Temporal trends are best derived through continuous monitoring of a population over a long period with the use of consistent diagnostic criteria. We describe temporal trends in the incidence of dementia over three decades among participants in the Framingham Heart Study.
    Methods: Participants in the Framingham Heart Study have been under surveillance for incident dementia since 1975. In this analysis, which included 5205 persons 60 years of age or older, we used Cox proportional-hazards models adjusted for age and sex to determine the 5-year incidence of dementia during each of four epochs. We also explored the interactions between epoch and age, sex, apolipoprotein E ε4 status, and educational level, and we examined the effects of these interactions, as well as the effects of vascular risk factors and cardiovascular disease, on temporal trends.
    Results: The 5-year age- and sex-adjusted cumulative hazard rates for dementia were 3.6 per 100 persons during the first epoch (late 1970s and early 1980s), 2.8 per 100 persons during the second epoch (late 1980s and early 1990s), 2.2 per 100 persons during the third epoch (late 1990s and early 2000s), and 2.0 per 100 persons during the fourth epoch (late 2000s and early 2010s). Relative to the incidence during the first epoch, the incidence declined by 22%, 38%, and 44% during the second, third, and fourth epochs, respectively. This risk reduction was observed only among persons who had at least a high school diploma (hazard ratio, 0.77; 95% confidence interval, 0.67 to 0.88). The prevalence of most vascular risk factors (except obesity and diabetes) and the risk of dementia associated with stroke, atrial fibrillation, or heart failure have decreased over time, but none of these trends completely explain the decrease in the incidence of dementia.
    Conclusions: Among participants in the Framingham Heart Study, the incidence of dementia has declined over the course of three decades. The factors contributing to this decline have not been completely identified. (Funded by the National Institutes of Health.).
    MeSH term(s) Aged ; Aged, 80 and over ; Atrial Fibrillation/complications ; Dementia/epidemiology ; Dementia/etiology ; Dementia, Vascular/epidemiology ; Educational Status ; Female ; Heart Failure/complications ; Humans ; Incidence ; Longitudinal Studies ; Male ; Massachusetts/epidemiology ; Middle Aged ; Proportional Hazards Models ; Risk Factors ; Stroke/complications
    Language English
    Publishing date 2016-01-06
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMoa1504327
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Apolipoprotein Proteomic Profiling for the Prediction of Cardiovascular Death in Patients with Heart Failure.

    Lemesle, Gilles / Chouraki, Vincent / de Groote, Pascal / Turkieh, Annie / Beseme, Olivia / Drobecq, Hervé / Amouyel, Philippe / Lamblin, Nicolas / Bauters, Christophe / Pinet, Florence

    Proteomics. Clinical applications

    2020  Volume 14, Issue 6, Page(s) e2000035

    Abstract: Purpose: Risk stratification in chronic systolic heart failure (HF) is critical to identify the patients who may benefit from advanced therapies. It is aimed at identifying new biomarkers to improve prognosis evaluation and help to better understand HF ... ...

    Abstract Purpose: Risk stratification in chronic systolic heart failure (HF) is critical to identify the patients who may benefit from advanced therapies. It is aimed at identifying new biomarkers to improve prognosis evaluation and help to better understand HF physiopathology.
    Experimental design: Prognostic evaluation is performed in 198 patients with chronic systolic HF: 99 patients who died from cardiovascular cause within three years are individually matched for age, sex, and HF etiology (ischemic vs not) with 99 patients who are alive after three years of HF evaluation. A proteomic profiling of 15 apolipoproteins (Apo) is performed: Apo-A1, -A2, -A4, -B100, -C1, -C2, -C3, -C4, -D, -E, -F, -H, -J, -L1, and -M using LC-MRM-MS.
    Results: In univariate analysis, the levels of Apo-B100 and -L1 are significantly lower and the levels of Apo-C1, -J, and -M are significantly higher in patients who died from cardiovascular cause as compared with patients alive. In the final statistical model, Apo-C1, Apo-J, and Apo-M improve individually the prediction of cardiovascular death. Ingenuity pathway analysis indicates these three Apo in a network associated with lipid metabolism, atherosclerosis signaling, and retinoid X receptor activation.
    Conclusions: Proteomic profiling of apolipoproteins using LC-MRM-MS might be useful in clinical practice for risk stratification of HF patients.
    MeSH term(s) Apolipoprotein C-I/blood ; Apolipoproteins M/blood ; Biomarkers/blood ; Clusterin/blood ; Female ; Heart Failure/blood ; Heart Failure/mortality ; Heart Failure/pathology ; Humans ; Male ; Middle Aged ; Models, Statistical ; Predictive Value of Tests ; Prognosis ; Proteome/metabolism ; Risk Factors
    Chemical Substances APOC1 protein, human ; APOM protein, human ; Apolipoprotein C-I ; Apolipoproteins M ; Biomarkers ; CLU protein, human ; Clusterin ; Proteome
    Language English
    Publishing date 2020-09-28
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2261788-7
    ISSN 1862-8354 ; 1862-8346
    ISSN (online) 1862-8354
    ISSN 1862-8346
    DOI 10.1002/prca.202000035
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke.

    Weinstein, Galit / Beiser, Alexa S / Preis, Sarah R / Courchesne, Paul / Chouraki, Vincent / Levy, Daniel / Seshadri, Sudha

    Alzheimer's & dementia (Amsterdam, Netherlands)

    2016  Volume 3, Page(s) 103–109

    Abstract: Introduction: Genetic variation in the clusterin gene has been associated with Alzheimer Disease (AD), and the clusterin protein is thought to play a mechanistic role. We explored the associations of clusterin plasma levels with incident dementia, AD, ... ...

    Abstract Introduction: Genetic variation in the clusterin gene has been associated with Alzheimer Disease (AD), and the clusterin protein is thought to play a mechanistic role. We explored the associations of clusterin plasma levels with incident dementia, AD, and stroke.
    Methods: Plasma clusterin was assessed in 1532 nondemented participants from the Framingham Study Offspring cohort between 1998 and 2001 (mean age, 69 ± 6; 53% women). We related clusterin levels to risk of incident dementia, AD, and stroke using Cox-proportional hazards models and examined potential interactions.
    Results: A significant interaction of plasma clusterin levels with age was observed. Clusterin was significantly associated with increased risk of dementia among elderly persons (>80 years; hazard ratio [HR], 95% confidence interval = 6.25, 1.64-23.89; P = .007) and with decreased risk of dementia (HR = 0.53, 0.32-0.88; P = .013) and stroke (HR = 0.78, 0.63-0.97; P = .029) among younger participants.
    Discussion: The association between plasma clusterin levels and risk of dementia and stroke may be modified by age or an age-related factor.
    Language English
    Publishing date 2016-07-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2832898-X
    ISSN 2352-8729
    ISSN 2352-8729
    DOI 10.1016/j.dadm.2016.06.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Whole exome sequence-based association analyses of plasma amyloid-β in African and European Americans; the Atherosclerosis Risk in Communities-Neurocognitive Study.

    Simino, Jeannette / Wang, Zhiying / Bressler, Jan / Chouraki, Vincent / Yang, Qiong / Younkin, Steven G / Seshadri, Sudha / Fornage, Myriam / Boerwinkle, Eric / Mosley, Thomas H

    PloS one

    2017  Volume 12, Issue 7, Page(s) e0180046

    Abstract: Objective: We performed single-variant and gene-based association analyses of plasma amyloid-β (aβ) concentrations using whole exome sequence from 1,414 African and European Americans. Our goal was to identify genes that influence plasma aβ42 ... ...

    Abstract Objective: We performed single-variant and gene-based association analyses of plasma amyloid-β (aβ) concentrations using whole exome sequence from 1,414 African and European Americans. Our goal was to identify genes that influence plasma aβ42 concentrations and aβ42:aβ40 ratios in late middle age (mean = 59 years), old age (mean = 77 years), or change over time (mean = 18 years).
    Methods: Plasma aβ measures were linearly regressed onto age, gender, APOE ε4 carrier status, and time elapsed between visits (fold-changes only) separately by race. Following inverse normal transformation of the residuals, seqMeta was used to conduct race-specific single-variant and gene-based association tests while adjusting for population structure. Linear regression models were fit on autosomal variants with minor allele frequencies (MAF)≥1%. T5 burden and Sequence Kernel Association (SKAT) gene-based tests assessed functional variants with MAF≤5%. Cross-race fixed effects meta-analyses were Bonferroni-corrected for the number of variants or genes tested.
    Results: Seven genes were associated with aβ in late middle age or change over time; no associations were identified in old age. Single variants in KLKB1 (rs3733402; p = 4.33x10-10) and F12 (rs1801020; p = 3.89x10-8) were significantly associated with midlife aβ42 levels through cross-race meta-analysis; the KLKB1 variant replicated internally using 1,014 additional participants with exome chip. ITPRIP, PLIN2, and TSPAN18 were associated with the midlife aβ42:aβ40 ratio via the T5 test; TSPAN18 was significant via the cross-race meta-analysis, whereas ITPRIP and PLIN2 were European American-specific. NCOA1 and NT5C3B were associated with the midlife aβ42:aβ40 ratio and the fold-change in aβ42, respectively, via SKAT in African Americans. No associations replicated externally (N = 725).
    Conclusion: We discovered age-dependent genetic effects, established associations between vascular-related genes (KLKB1, F12, PLIN2) and midlife plasma aβ levels, and identified a plausible Alzheimer's Disease candidate gene (ITPRIP) influencing cell death. Plasma aβ concentrations may have dynamic biological determinants across the lifespan; plasma aβ study designs or analyses must consider age.
    MeSH term(s) African Americans/genetics ; Aged ; Amyloid beta-Peptides/blood ; European Continental Ancestry Group/genetics ; Exome ; Female ; Gene Regulatory Networks ; Genome-Wide Association Study/methods ; Humans ; Male ; Middle Aged ; Polymorphism, Single Nucleotide ; Sequence Analysis, DNA/methods ; United States/ethnology
    Chemical Substances Amyloid beta-Peptides
    Language English
    Publishing date 2017-07-13
    Publishing country United States
    Document type Journal Article
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0180046
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study.

    Chouraki, Vincent / Preis, Sarah R / Yang, Qiong / Beiser, Alexa / Li, Shuo / Larson, Martin G / Weinstein, Galit / Wang, Thomas J / Gerszten, Robert E / Vasan, Ramachandran S / Seshadri, Sudha

    Alzheimer's & dementia : the journal of the Alzheimer's Association

    2017  Volume 13, Issue 12, Page(s) 1327–1336

    Abstract: Introduction: The identification of novel biomarkers associated with Alzheimer's disease (AD) could provide key biological insights and permit targeted preclinical prevention. We investigated circulating metabolites associated with incident dementia and ...

    Abstract Introduction: The identification of novel biomarkers associated with Alzheimer's disease (AD) could provide key biological insights and permit targeted preclinical prevention. We investigated circulating metabolites associated with incident dementia and AD using metabolomics.
    Methods: Plasma levels of 217 metabolites were assessed in 2067 dementia-free Framingham Offspring Cohort participants (mean age = 55.9 ± 9.7 years; 52.4% women). We studied their associations with future dementia and AD risk in multivariate Cox models.
    Results: Ninety-three participants developed incident dementia (mean follow-up = 15.6 ± 5.2 years). Higher plasma anthranilic acid levels were associated with greater risk of dementia (hazard ratio [HR] = 1.40; 95% confidence interval [CI] = [1.15-1.70]; P = 8.08 × 10
    Discussion: We identified four biologically plausible, candidate plasma biomarkers for dementia. Association of anthranilic acid implicates the kynurenine pathway, which modulates glutamate excitotoxicity. The associations with hypoxanthine and taurine strengthen evidence that uric acid and taurine may be neuroprotective.
    MeSH term(s) Adolescent ; Adult ; Aged ; Alzheimer Disease/blood ; Alzheimer Disease/epidemiology ; Amines/blood ; Child ; Child of Impaired Parents ; Child, Preschool ; Cohort Studies ; Dementia/blood ; Dementia/epidemiology ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Young Adult
    Chemical Substances Amines
    Language English
    Publishing date 2017-06-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2211627-8
    ISSN 1552-5279 ; 1552-5260
    ISSN (online) 1552-5279
    ISSN 1552-5260
    DOI 10.1016/j.jalz.2017.04.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Meta-analysis of genome-wide association studies identifies ancestry-specific associations underlying circulating total tau levels.

    Sarnowski, Chloé / Ghanbari, Mohsen / Bis, Joshua C / Logue, Mark / Fornage, Myriam / Mishra, Aniket / Ahmad, Shahzad / Beiser, Alexa S / Boerwinkle, Eric / Bouteloup, Vincent / Chouraki, Vincent / Cupples, L Adrienne / Damotte, Vincent / DeCarli, Charles S / DeStefano, Anita L / Djoussé, Luc / Fohner, Alison E / Franz, Carol E / Kautz, Tiffany F /
    Lambert, Jean-Charles / Lyons, Michael J / Mosley, Thomas H / Mukamal, Kenneth J / Pase, Matthew P / Portilla Fernandez, Eliana C / Rissman, Robert A / Satizabal, Claudia L / Vasan, Ramachandran S / Yaqub, Amber / Debette, Stephanie / Dufouil, Carole / Launer, Lenore J / Kremen, William S / Longstreth, William T / Ikram, M Arfan / Seshadri, Sudha

    Communications biology

    2022  Volume 5, Issue 1, Page(s) 336

    Abstract: Circulating total-tau levels can be used as an endophenotype to identify genetic risk factors for tauopathies and related neurological disorders. Here, we confirmed and better characterized the association of the 17q21 MAPT locus with circulating total- ... ...

    Abstract Circulating total-tau levels can be used as an endophenotype to identify genetic risk factors for tauopathies and related neurological disorders. Here, we confirmed and better characterized the association of the 17q21 MAPT locus with circulating total-tau in 14,721 European participants and identified three novel loci in 953 African American participants (4q31, 5p13, and 6q25) at P < 5 × 10
    MeSH term(s) Black or African American/genetics ; Alzheimer Disease/genetics ; Exome ; Genome-Wide Association Study ; Humans ; Tauopathies
    Language English
    Publishing date 2022-04-08
    Publishing country England
    Document type Journal Article ; Meta-Analysis
    ISSN 2399-3642
    ISSN (online) 2399-3642
    DOI 10.1038/s42003-022-03287-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.

    Chouraki, Vincent / Beiser, Alexa / Younkin, Linda / Preis, Sarah Rosner / Weinstein, Galit / Hansson, Oskar / Skoog, Ingmar / Lambert, Jean-Charles / Au, Rhoda / Launer, Lenore / Wolf, Philip A / Younkin, Steven / Seshadri, Sudha

    Alzheimer's & dementia : the journal of the Alzheimer's Association

    2014  Volume 11, Issue 3, Page(s) 249–57.e1

    Abstract: Background: Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the ... ...

    Abstract Background: Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date.
    Methods: A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD.
    Results: Increased plasma Aβ1-42 levels were associated with lower risk of dementia (Aβ1-42: hazard ratio [HR] = 0.80 [0.71‒0.90], P < .001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.86 [0.76‒0.98], P = .027) and AD (Aβ1-42: HR = 0.79 [0.69‒0.90], P < .001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.83 [0.72‒0.96], P = .012).
    Conclusion: Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.
    MeSH term(s) Aged ; Alzheimer Disease/blood ; Alzheimer Disease/diagnosis ; Amyloid beta-Peptides/blood ; Biomarkers/blood ; Female ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Peptide Fragments/blood ; Proportional Hazards Models ; Prospective Studies ; Risk ; Survival Analysis
    Chemical Substances Amyloid beta-Peptides ; Biomarkers ; Peptide Fragments ; amyloid beta-protein (1-40) ; amyloid beta-protein (1-42)
    Language English
    Publishing date 2014-09-10
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Research Support, N.I.H., Extramural ; Research Support, N.I.H., Intramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2211627-8
    ISSN 1552-5279 ; 1552-5260
    ISSN (online) 1552-5279
    ISSN 1552-5260
    DOI 10.1016/j.jalz.2014.07.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants.

    Damotte, Vincent / van der Lee, Sven J / Chouraki, Vincent / Grenier-Boley, Benjamin / Simino, Jeannette / Adams, Hieab / Tosto, Giuseppe / White, Charles / Terzikhan, Natalie / Cruchaga, Carlos / Knol, Maria J / Li, Shuo / Schraen, Susanna / Grove, Megan L / Satizabal, Claudia / Amin, Najaf / Berr, Claudine / Younkin, Steven / Gottesman, Rebecca F /
    Buée, Luc / Beiser, Alexa / Knopman, David S / Uitterlinden, Andre / DeCarli, Charles / Bressler, Jan / DeStefano, Anita / Dartigues, Jean-François / Yang, Qiong / Boerwinkle, Eric / Tzourio, Christophe / Fornage, Myriam / Ikram, M Arfan / Amouyel, Philippe / de Jager, Phil / Reitz, Christiane / Mosley, Thomas H / Lambert, Jean-Charles / Seshadri, Sudha / van Duijn, Cornelia M

    Alzheimer's & dementia : the journal of the Alzheimer's Association

    2021  Volume 17, Issue 10, Page(s) 1663–1674

    Abstract: Introduction: There is increasing interest in plasma amyloid beta (Aβ) as an endophenotype of Alzheimer's disease (AD). Identifying the genetic determinants of plasma Aβ levels may elucidate important biological processes that determine plasma Aβ ... ...

    Abstract Introduction: There is increasing interest in plasma amyloid beta (Aβ) as an endophenotype of Alzheimer's disease (AD). Identifying the genetic determinants of plasma Aβ levels may elucidate important biological processes that determine plasma Aβ measures.
    Methods: We included 12,369 non-demented participants from eight population-based studies. Imputed genetic data and measured plasma Aβ1-40, Aβ1-42 levels and Aβ1-42/Aβ1-40 ratio were used to perform genome-wide association studies, and gene-based and pathway analyses. Significant variants and genes were followed up for their association with brain positron emission tomography Aβ deposition and AD risk.
    Results: Single-variant analysis identified associations with apolipoprotein E (APOE) for Aβ1-42 and Aβ1-42/Aβ1-40 ratio, and BACE1 for Aβ1-40. Gene-based analysis of Aβ1-40 additionally identified associations for APP, PSEN2, CCK, and ZNF397. There was suggestive evidence for interaction between a BACE1 variant and APOE ε4 on brain Aβ deposition.
    Discussion: Identification of variants near/in known major Aβ-processing genes strengthens the relevance of plasma-Aβ levels as an endophenotype of AD.
    MeSH term(s) Alzheimer Disease/genetics ; Amyloid/blood ; Amyloid/metabolism ; Amyloid Precursor Protein Secretases/genetics ; Amyloid beta-Protein Precursor/genetics ; Apolipoproteins E/genetics ; Aspartic Acid Endopeptidases/genetics ; Brain/metabolism ; Genome-Wide Association Study ; Healthy Volunteers ; Humans ; Positron-Emission Tomography ; Presenilin-2/genetics
    Chemical Substances Amyloid ; Amyloid beta-Protein Precursor ; ApoE protein, human ; Apolipoproteins E ; PSEN2 protein, human ; Presenilin-2 ; Amyloid Precursor Protein Secretases (EC 3.4.-) ; Aspartic Acid Endopeptidases (EC 3.4.23.-) ; BACE1 protein, human (EC 3.4.23.46)
    Language English
    Publishing date 2021-05-18
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2211627-8
    ISSN 1552-5279 ; 1552-5260
    ISSN (online) 1552-5279
    ISSN 1552-5260
    DOI 10.1002/alz.12333
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Importance des troubles de la personnalité et des comorbidités psychiatriques chez 30 patients atteints de fibromyalgie.

    Rose, Sébastien / Cottencin, Olivier / Chouraki, Vincent / Wattier, Jean-Michel / Houvenagel, Eric / Vallet, Benoit / Goudemand, Michel

    Presse medicale (Paris, France : 1983)

    2009  Volume 38, Issue 5, Page(s) 695–700

    Abstract: Unlabelled: WORK INTEREST: To assess vulnerability factors of outpatients with fibromyalgia, by the evaluating prevalence of DSM-IV axis I disorders (mental disorders) and axis II disorders (personality disorders).: Methods: 30 outpatients with ... ...

    Title translation Study on personality and psychiatric disorder in fibromyalgia.
    Abstract Unlabelled: WORK INTEREST: To assess vulnerability factors of outpatients with fibromyalgia, by the evaluating prevalence of DSM-IV axis I disorders (mental disorders) and axis II disorders (personality disorders).
    Methods: 30 outpatients with fibromyalgia were examined consecutively, and were administered the Mini International Neuropsychiatric Interview and the Structured Clinical Interview for DSM-IV.
    Results: The patients were found to have a high prevalence of DSM-IV axis I disorders (63,3% received a diagnosis of depressive and/or anxious disorder), and axis II disorders (46,7% received at least one diagnosis of personality disorder, including obsessive-compulsive personality disorder: 30%, borderline personality disorder: 16,7%, and depressive personality disorder: 16,7%).
    Perspectives: Our results show the importance of psychiatric comorbidities, including personality disorders from outpatients with fibromyalgia. Personality disorders have to be taken into account in the treatment by their impact on doctor-patient relation. Our results suggest the importance of liaison psychiatry in the treatment of those patients.
    MeSH term(s) Comorbidity ; Drug Utilization ; Female ; Fibromyalgia/complications ; Fibromyalgia/psychology ; Humans ; Interview, Psychological ; Male ; Mental Disorders/complications ; Mental Disorders/diagnosis ; Mental Disorders/drug therapy ; Middle Aged ; Psychotropic Drugs/therapeutic use
    Chemical Substances Psychotropic Drugs
    Language French
    Publishing date 2009-05
    Publishing country France
    Document type English Abstract ; Journal Article
    ZDB-ID 120943-7
    ISSN 2213-0276 ; 0032-7867 ; 0755-4982 ; 0301-1518
    ISSN (online) 2213-0276
    ISSN 0032-7867 ; 0755-4982 ; 0301-1518
    DOI 10.1016/j.lpm.2008.11.013
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top